What is the catalog number for SU9516?

The catalog number for SU9516 is HY-18629.

What sizes are available for SU9516?

SU9516 is available in the following size(s): 1 mg, 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does SU9516 come in?

SU9516 is available in 7 different pack sizes.

SU9516 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures SU9516?

SU9516 is manufactured by QuantiMol.

What is the estimated delivery time for SU9516?

Estimated delivery time for SU9516 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for SU9516?

The safety data sheet for SU9516 is available here: http://file.medchemexpress.com/batch_PDF/HY-18629/SU9516-SDS-MedChemExpress.pdf.

SU9516

SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC50s of 40, 200 nM, respectively.

Product Specifications

CAS Number

377090-84-1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; CDK

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SU9516.html

Purity

99.85

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1NC2=C(C=C(OC)C=C2)/C1=C/C3=CN=CN3

Molecular Formula

C13H11N3O2

Molecular Weight

241.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Lane ME, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 2001 Aug 15;61 (16) :6170-7.|[2]Yu B, et al. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochem Pharmacol. 2002 Oct 1;64 (7) :1091-100.|[3]Gao N, et al. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1- (3H-imidazol-4-yl) -meth- (Z) -ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol. 2006 Aug;70 (2) :645-55.